HOME >> BIOLOGY >> NEWS
Idun develops new drug screen for treatments of stroke, heart attack, and cancer

Key apoptosis reaction adaptable to high throughput screening

KEYSTONE, Colorado, January 22, 2001 - Idun Pharmaceuticals, Inc. described the successful recreation in the lab of a key biological reaction that occurs in human cells and is part of the apoptosis pathway. This assay is being used to help understand the mechanism of apoptosis at the molecular level and to screen new drugs that modulate apoptosis. This development was presented at the Molecular Mechanisms of Apoptosis Meeting in Keystone, Colorado.

In the study, entitled, Reconstitution of Apaf-4/Procaspase-9 Holoenzyme-Mediated Procaspase-3 Activation: Requirement for Caspase-9 Conformational Change or Apaf-1 Association, it was shown that recombinant components of the human apoptosis pathway can be combined in vitro to carry out the activation of one of the key components that triggers programmed cell death.

Developing a key apoptosis reaction in vitro that mimics a natural in vivo reaction has important applications, both for use as a drug screen and as a tool to better understand how apoptosis is regulated, said Dr. Kevin Tomaselli, Vice President, Discovery Research and Co-Founder of Idun Pharmaceuticals. This gives us the ability to screen for drugs in a high throughput format that modulate apoptosis by affecting this specific apoptosis reaction.

Iduns expertise and success in apoptosis encompasses the entire breadth of cutting edge biotechnology, said Steven Mento, Ph.D., President and CEO of Idun Pharmaceuticals. We bring together the disciplines of gene discovery, functional genomics, high throughput screening (HTS), biochemical validation, structural modeling, and targeted drug development and apply them to the discovery and characterization of human apoptosis genes. This includes determining the function of the genes and their role in disease. Based on that, we develop new drugs to treat important human diseases such as cancer, heart attacks and stroke. N
'"/>

Contact: Lora Pike
l.pike@noonanrusso.com
415-677-4455 ext.211
Noonan/Russo Communications
21-Jan-2001


Page: 1 2

Related biology news :

1. Carnegie Mellon neuroscientist develops tool to image brain function at the cellular level
2. Carnegie Mellon U. develops microgel to recover enzymes for manufacturing, research assays
3. Scientists findings may lead to better understanding of how that sleep develops, matures
4. Fox Chase Cancer Center researcher develops new model for studying prions mad cow disease
5. US develops lethal new viruses
6. Brookhaven Lab develops ThraxVac to clean up anthrax
7. Carnegie Mellon develops new process for growing bone
8. Cancer could be caught before it develops
9. St. Jude develops vaccine against potential pandemic influenza virus H5N1 using reverse genetics
10. University of Ulster develops DNA fingerprint techniques to fight bio-terrorism
11. Clothing from Corn: DuPont develops innovative process to create polymer from renewable resources

Post Your Comments:
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, Inc. ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a primary commercial focus on ... been granted a Type C meeting with the U.S. ... will be held in February 2015.  During this meeting ...
(Date:12/15/2014)... , Dec. 15, 2014 Organovo ... biology company focused on delivering breakthrough 3D bioprinting ... industry and collaborators of its exVive3D TM ... widely available in full commercial release on November ... field, resulting in several awards for innovation. ...
(Date:12/13/2014)... MaRS and Virgin Unite Canada, the non-profit foundation of the ... support Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... MaRS Centre to announce the new partnership, which includes the ... has $1 million in seed capital provided by Virgin Unite ... Innovation Foundation, founded by Alison Lawton . ...
(Date:12/13/2014)... According to population studies: “North Carolina ... and 2030." If a population explosion like that actually ... state in the country. , To that end, North ... of North Carolina Forum on December 16th to ask ... necessary infrastructure in place? Enough clean water? And will ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2
Cached News: